AORT — Artivion, Inc.

Summary of Artivion, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $116.3 million, up 12% year-over-year.
• Adjusted EBITDA: Increased to $22.1 million, a 26% rise from $17.5 million in Q1 2025, with an adjusted EBITDA margin of 19%.
• Revenue Growth by Product Line:
  • Stent grafts: +10%
  • On-X: +17%
  • Tissue processing: +23%
  • BioGlue: Flat year-over-year.
• Geographic Revenue Growth:
  • North America: +23%
  • Asia Pacific: +6%
  • EMEA: +5%
  • Latin America: -23%
• Gross Margin: Improved to 64.9% from 64.2% in Q1 2025.
• Free Cash Flow: Negative $6.8 million, an improvement from negative $20.6 million in Q1 2025.
• Debt: $215.4 million with a net leverage ratio of 1.8x, down from 4.0x year-over-year.

2. Strategic Updates and Business Highlights

• Acquisition of Endospan: Artivion plans to acquire Endospan and its NEXUS aortic arch stent graft system, which has received PMA approval. This acquisition is expected to complete Artivion's aortic arch portfolio.
• Product Development: The ARTISON clinical trial for the next-generation frozen elephant trunk is progressing, with 26 patients enrolled.
• Market Positioning: Artivion aims to leverage its comprehensive aortic arch portfolio and expects to launch NEXUS in January 2027.

3. Forward Guidance and Outlook

• Adjusted Revenue Growth Guidance: Revised to 7%-11% for full-year 2026, translating to $480 million to $496 million in reported revenue.
• Adjusted EBITDA Guidance: Expected to be $100 million to $107 million, with potential reduction to $92 million to $99 million due to the Endospan acquisition costs.
• Sales Expectations: Anticipated PMA approval for AMDS in mid-2026, which is expected to facilitate new account conversions and increase sales.

4. Bad News, Challenges, or Points of Concern

• Stent Graft Sales: Q1 results for stent grafts fell below expectations due to lower AMDS starter set sales and softer international performance, particularly in the Middle East.
• International Market Challenges: Declining revenue in Latin America and fluctuations in distributor ordering patterns in Asia Pacific.
• PMA Approval Delays: Some hospitals are deferring AMDS adoption due to pending PMA approval, impacting starter set sales.
• Supply Chain Issues: Ongoing challenges related to the supplier network, which may affect product availability and sales.

5. Notable Q&A Insights

• AMDS Sales Dynamics: Management indicated that while implant sales are strong, the upfront $100,000 cost for starter sets is a barrier for new accounts. They are working on strategies to mitigate this.
• NEXUS Launch Preparation: Plans include building inventory and hiring clinical specialists to support the U.S. launch.
• Reordering Behavior: Positive trends in reordering from existing accounts were noted, suggesting strong user experience with AMDS.
• International Performance: The decline in international sales was attributed to specific regional challenges, with expectations for normalization as issues are addressed.

Overall, while Artivion demonstrated solid financial growth in Q1 2026, challenges in international markets and AMDS sales present headwinds that the company is actively working to overcome. The strategic acquisition of Endospan and the expected PMA approval for AMDS are anticipated to drive future growth.